3 September 2015 - The Canadian pERC has published a draft recommendation in favour of the use of ramucirumab (Cyramza) when used in combination with paclitaxel for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma after prior chemotherapy, so long as its cost effectiveness is improved to an acceptable level.  It use as monotherapy has not been recommended.

The date for the publication of a final recommendaton has not been set.

For more details, go to: https://www.cadth.ca/cyramza-advanced-gc-or-gej-adenocarcinoma-details

MAESTrO Insight: This is the first full HTA agency outcome for ramucirumab; insofar as it is an orphan drug (in the EU), the IQWiG did not undertake an full assessment. In France, ramucirumab was given an SMR of moderate and an ASMR of V when used in combination and an ASMR of VI when used as monotherapy.